Bioanalytical approach to accelerate development efforts in
the identification of compounds that can treat chlorine or sulfur
mustard injuries
LONDON, Nov. 8, 2021 /PRNewswire/ -- Clarivate Plc
(NYSE: CLVT), a global leader in providing trusted information and
insights to accelerate the pace of innovation, today announced a
new partnership with the Biomedical Advanced Research and
Development Authority (BARDA), which provides an integrated,
systematic approach to the development of the necessary vaccines,
drugs, therapies, and diagnostic tools for public health medical
emergencies. The new collaboration will leverage Clarivate
Consulting Service's computational approach in identifying
therapeutics for potential repurposing as medical countermeasures
(MCMs) against chlorine and sulfur mustard induced injuries.
Drug repurposing evaluates new uses, outside of the original
clinical indication, for therapeutics approved by the U.S. Food and
Drug Administration (FDA) or in late-stage development. BARDA
funding will aid in target identification and drug factor analyses
to identify potential drugs for repurposing to treat chemical agent
exposure. These drugs may affect biological pathways that are
implicated in chemical agent exposure or in the body's response to
it and may already treat analogous diseases with similar biology
but different causes. Such drugs, particularly when highly
available in our pharmaceutical supply chain, may be studied and
developed in an accelerated manner to provide reserve capacity in
response to exposure events.
Many chemical threats exist that can inflict injuries rapidly,
and MCMs must be readily available to mitigate these risks. With
conventional drug discovery involving costly and lengthy studies,
using machine learning and artificial intelligence (AI) to identify
and prioritize new targets for drug discovery and therapeutics that
can be repurposed would help reduce the time and cost of
preclinical drug development.
As a company at the forefront of target identification,
indication prioritization, mechanism reconstruction and drug
repurposing work in the pharmaceutical industry, Clarivate will
identify drugs that are commonly available and can be used as MCMs
for exposure to chemical agents. The Clarivate suite of research
intelligence solutions used in the project will include MetaBase,
Cortellis Drug Discovery Intelligence, OFF-X, and real-world data
featured within the Clarivate Research Intelligence Cloud. Paired
with deep domain expertise, Clarivate will evaluate genomic
experiments, systems and computational biology, as well as known
protein-protein interactions and molecular pathways accessed
through its proprietary curated databases. This approach is
expected to provide a fast, focused method for screening drug
candidates most likely to be repurposed successfully for treating
chemical exposures.
Mukhtar Ahmed, President, Science
Group, Clarivate, said: "We are honored to be selected to partner
with BARDA to identify medical countermeasures to treat chlorine
gas exposure and the ocular and respiratory effects of sulfur
mustard exposure. Clarivate will leverage its advanced products and
consulting services teams designed to accelerate the pace of
discovery and innovation, including its vast data sets and advanced
analytics to enable faster evidence-based decision-making. These
efforts will unlock hidden insights and provide new and unique
perspectives using intelligence in ways not previously available to
analyze relevant therapeutics."
This effort to leverage AI is the first of its kind funded
through the Repurposing Drugs in Response to Chemical Threats
(ReDIRECT) program under BARDA's Division of Research, Innovation,
and Ventures (DRIVe). The award is one component of BARDA's
Chemical, Biological, Radiological, and Nuclear (CBRN) medical
countermeasures and DRIVe's ReDIRECT portfolios.
This project has been funded in whole or in part with Federal
funds from the Department of Health and Human Services; Office of
the Assistant Secretary for Preparedness and Response; Biomedical
Advanced Research and Development Authority, under Contract No.
75A50121C00031.
To learn more about the collaboration, visit DRIVe's
ReDIRECT program here [https://drive.hhs.gov/ReDIRECT.html].
About Clarivate
Clarivate™ is a global leader in providing solutions to
accelerate the lifecycle of innovation. Our bold mission is to help
customers solve some of the world's most complex problems by
providing actionable information and insights that reduce the time
from new ideas to life-changing inventions in the areas of science
and intellectual property. We help customers discover, protect and
commercialize their inventions using our trusted subscription and
technology-based solutions coupled with deep domain expertise. For
more information, please visit clarivate.com.
Media Contact:
Catherine Daniel
media.enquiries@clarivate.com
Forward-Looking Statements
This press release and any statements included herein may
contain forward-looking statements regarding Clarivate.
Forward-looking statements provide current expectations or
forecasts of future events and may include statements regarding
results, anticipated events and other future expectations. These
statements involve risks and uncertainties including factors
outside of the control of Clarivate that may cause actual results
to differ materially. Clarivate undertakes no obligation to update
or revise the statements made herein, whether as a result of new
information, future events or otherwise.
Logo -
https://mma.prnewswire.com/media/1159266/Clarivate_Logo.jpg